Trial Profile

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVL 330 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Acronyms HEROEX-1
Sponsors Nuvalent

Most Recent Events

20 Jul 2025 Planned number of patients changed from 120 to 150.
23 Apr 2025 According to a Nuvalent media release, trial in progress data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
13 Jan 2025 According to a Nuvalent media release, the company to progress this trial in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com